| Specialty Retail Industry | Consumer Discretionary Sector | - CEO | TWSE Exchange | TW0004132006 ISIN |
| Taiwan Country | - Employees | - Last Dividend | 29 Nov 2021 Last Split | - IPO Date |
Golden Biotechnology Corporation is a prominent entity specializing in drug discovery and the manufacturing of health food supplements. Since its inception in 2002, it has established a notable presence not only in its home country, Taiwan, but also internationally, including in the United States, Japan, China, Korea, and Singapore. The company’s efforts are geared towards the development of innovative health solutions, with a significant focus on addressing various health issues such as cancer, liver health, fatigue, autoimmune diseases, and general wellness. Positioned at the forefront of biotechnology, Golden Biotechnology Corporation leverages cutting-edge research to contribute to the betterment of health outcomes globally. Its headquarters are located in New Taipei City, Taiwan.
Designed to support liver health and alleviate fatigue, Liverty is a testament to Golden Biotechnology Corporation's commitment to developing products that support vital organ functions and enhance overall vitality.
This product serves as an auto-immune adjuvant therapy, offering a complementary approach to traditional autoimmune disease treatments. Rasle exemplifies the company’s dedication to innovative health solutions.
A nourishment product aimed at assisting individuals in recovery from illness and promoting general health improvement. ZSAINO represents the company's focus on enhancing quality of life through nutritional support.
A herbal formula targeted at optimizing male health. UMOOZE reflects Golden Biotechnology Corporation’s approach to natural and holistic health remedies.
As a pioneering anticancer molecule, Antroquinonol is under development for treating a range of conditions including pancreatic cancer, acute myeloid leukemia, hepatocellular carcinoma, as well as hypercholesterolemia and hyperlipidemia. This flagship product underscores the company’s commitment to groundbreaking research in cancer treatment and cardiovascular health.